typhoid vi polysaccharide vaccine
Trade name: Typhim Vi
Vaccineapproved
Approved
Nov 28, 1994
The Vi capsular polysaccharide vaccine is a typhoid vaccine recommended by the World Health Organization for the prevention of typhoid. The vaccine was first licensed in the US in 1994 and is made from the purified Vi capsular polysaccharide from the Ty2 Salmonella Typhi strain; it is a subunit vaccine. — Wikipedia
Clinical trial activity
38 trials · 42 clinical orgs · 1 marketing orgs
Phase 1
13
Phase 2
16
Phase 3
8
Phase 4
7
Earliest trial started Oct 1, 2001 (NCT00131833)
Timeline
1990s
- Nov 28, 1994
Earliest FDA Approval
2000s
- Feb 4, 2000
Sanofi-Aventis — First NDA Organization
- Feb 4, 2000
Sanofi-Aventis — NDA Secondary Org
- Feb 4, 2000
Sanofi-Aventis — NDA Organization
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Studied for
- Acute Coronary Syndrome · Phase 1
- Bacterial Infections · Phase 3
- Cholera · Phase 3
- Deficiency Diseases · Phase 4
- Diarrhea · Phase 1/Phase 2
- Encephalitis, Japanese · Phase 3
- Healthy Volunteers · Phase 4
- Hepatitis A · Phase 4
- Inflammation · Phase 1
- Influenza, Human · Phase 4
- Malaria · Phase 2
- Measles · Phase 3
- Meningitis, Meningococcal · Phase 3
- Meningococcal Infections · Phase 3
- Mpox, Monkeypox · Phase 4
- Myocardial Infarction · Phase 1
- Paratyphoid Fever · Phase 4
- Rabies · Phase 3
- Reperfusion Injury · Phase 1
- Rubella · Phase 3
- Salmonella · Phase 2
- Salmonella Infections · Phase 3
- Stress Disorders, Post-Traumatic · Phase 1
- Typhoid Fever · Phase 4
- Typhoid-Paratyphoid Vaccines · Phase 3
- Yellow Fever · Phase 3
Mechanism of action
- Salmonella typhiImmunity, active
Salmonella typhi immunity, active
Approval history
- approvedNov 28, 1994
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVi capsular polysaccharide vaccine ↗
Also known as
- pedatyph
- typhim vi
- typhim vi
- typhim vi
- typhoid fever vaccine
- typhoid vi polysaccharide vaccine
- vi polysaccharide
- vi polysaccharide vaccine, typhoid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06757283 | Phase 3 | Apr 1, 2025 | International Center for Diarrheal Disease Research, Zydus Discovery DMCC |
| NCT06630884 | Phase 1 | Nov 30, 2024 | Department of Veteran Affairs, National Institute of Mental Health (NIMH), Northern California Institute of Research and Education, University of California, San Francisco |
| NCT06116669 | N/A | Nov 5, 2023 | Jomo Kenyatta University of Agriculture and Technology, Swiss Federal Institute of Technology, University of Oxford |
| NCT05771779 | Phase 3 | Oct 14, 2023 | Centers for Disease Control and Prevention (CDC), International Center for Diarrheal Disease Research |
| NCT06027801 | N/A | Sep 6, 2023 | Government of Thailand, Mahidol University, University of Oxford |
| NCT05745987 | Phase 4 | Jul 1, 2023 | McMaster University |
| NCT05784701 | Phase 2 | Apr 5, 2023 | University of Maryland, Wellcome Trust |
| NCT05794230 | Phase 3 | Mar 27, 2023 | Sanofi-Aventis |
| NCT05613205 | Phase 1 | Nov 8, 2022 | BE Pharmaceuticals, GlaxoSmithKline |
| NCT05475379 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2022 | International Center for Diarrheal Disease Research |
| NCT05346302 | Early Phase 1 (Phase 1) | Feb 8, 2022 | Department of Defense, Philips, Texas A&M University |
| NCT05073003 | Phase 1/Phase 2 (Phase 2) | Oct 6, 2021 | GlaxoSmithKline |
| NCT04830371 | Phase 2/Phase 3 (Phase 3) | Sep 7, 2020 | EuBiologics Co.,Ltd |
| NCT04051268 | Phase 3 | Oct 30, 2019 | PT Bio Farma, University of Indonesia |
| NCT03933098 | Phase 3 | Aug 31, 2019 | International Vaccine Institute, Kanti Children's Hospital, SK Bioscience Co., Ltd. |
| NCT03917654 | Phase 2 | Jul 5, 2019 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03956524 | Phase 1 | Mar 16, 2019 | EuBiologics Co.,Ltd |
| NCT03460405 | Phase 2 | Jul 16, 2018 | PT Bio Farma, University of Indonesia |
| NCT03294564 | Early Phase 1 (Phase 1) | Jan 1, 2018 | National Institute of Mental Health (NIMH), University of California, San Francisco |
| NCT03312699 | Phase 4 | Sep 19, 2017 | National Institute of Allergy and Infectious Diseases (NIAID), Stanford University |
Showing 20 of 38 trials
Page 1 / 2
Organizations
Research & Development (42)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| International Vaccine Institute | Academic/Hospital | 6 | 6 | 3 | 2001 |
| GlaxoSmithKline | For profit | 5 | 2 | 3 | 2001 |
| Wellcome Trust | Academic/Hospital | 5 | 0 | 2 | 2001 |
| Novartis | For profit | 4 | 4 | 2 | 2010 |
| University of Western Ontario | Academic/Hospital | 4 | 0 | 1 | 2001 |
| International Center for Diarrheal Disease Research | Academic/Hospital | 3 | 3 | 2 | 2022 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 2 | 3 | 2006 |
| National Institute of Mental Health (NIMH) | Government | 3 | 0 | 1 | 2017 |
| PT Bio Farma | For profit | 3 | 3 | 3 | 2017 |
| University of California, San Francisco | Academic/Hospital | 3 | 3 | 1 | 2017 |
| University of Indonesia | Academic/Hospital | 3 | 0 | 3 | 2017 |
| University of Oxford | Academic/Hospital | 3 | 2 | 2 | 2015 |
| Centers for Disease Control and Prevention (CDC) | Government | 2 | 0 | 2 | 2001 |
| EuBiologics Co.,Ltd | For profit | 2 | 2 | 2 | 2019 |
| Sanofi-Aventis | For profit | 2 | 1 | 1 | 2012 |
| Aga Khan University | Academic/Hospital | 1 | 0 | 1 | 2001 |
| BE Pharmaceuticals | For profit | 1 | 0 | 1 | 2022 |
| Department of Defense | Government | 1 | 0 | 1 | 2022 |
| Department of Veteran Affairs | Government | 1 | 0 | 1 | 2024 |
| Government of China | Government | 1 | 0 | 1 | 2001 |
42 organizations
Page 1 / 3
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Sanofi-Aventis | For profit | NDA2 | Feb 4, 2000 |
| Sanofi-Aventis | For profit | NDA | Feb 4, 2000 |